Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1413-1416

  Roukos, Dimitrios H ^a   Tzakos, Andreas ^b   Zografos, George ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; PANITUMUMAB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC THERAPY; BLEEDING; BREAST CANCER; CANCER INVASION; CANCER RESISTANCE; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GLIOBLASTOMA; HUMAN; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350593945     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.116     Document Type: Editorial

References (20)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
2. Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 458(7236) 290-292 (2009).
3. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009).
4. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232-239 (2009).
5. Jain RK, Duda DG, Clark JW et al. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24-40 (2006).
6. Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol. 4, 181-189 (2007).
7. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27(13), 2231-2237 (2009).
8. Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn. 9(3), 217-221 (2009).
9. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353(16),1652-1654 (2005).
10. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962-972 (2008).
11. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008).
12. Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
13. Bastiaens P. Systems biology: when it is time to die. Nature 459(7245), 334-335 (2009).
14. Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
15. Roukos DH. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 358(15), 1636 (2008).
16. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
17. Deisboeck TS, Zhang L, Yoon J, Costa J. In silico cancer modeling: is it ready for prime time? Nat. Clin. Pract. Oncol. 6(1), 34-42 (2009).
18. Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev. Mol. Diagn. 9(3), 227-229 (2009).
19. Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol. Syst. Biol. 5, 249 (2009).
20. Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann. Surg. 249(6), 1067-1068 (2009).